Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cangrelor procedural platelet inhibition in pediatric congenital heart disease
2025-523109-14-00Phase 3Authorised
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jun 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of cangrelor in Cardiovascular Malformation (CVM), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Bleeding events within 72 hours, Hemoderivative transfusion and 6 more. Planned start Jun 2026; status: authorised.
02
Drugs
cangrelor
03
Conditions
Cardiovascular Malformation (CVM)
Beyond the preview
Go deeper on 2025-523109-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523109-14-00.